Welcome to the ScanSource quarterly earnings conference call. (Operator Instructions) Today's call is being recorded. (Operator Instructions) I would now like to turn the call over to Mary Gentry ...

Revenue: US$704.8m (down 6.3% from 3Q 2024). Net income: US$17.4m (up 36% from 3Q 2024). Profit margin: 2.5% (up from 1.7% in 3Q 2024). The increase in margin was driven by lower expenses. EPS: US ...

Welcome to the ScanSource quarterly earnings conference call. All lines have been placed on a listen-only mode until the question-and-answer session. Today's call is being recorded. If anyone has ...

ScanSource, Inc. has a one year low of $28.75 and a one year high of $53.90. The stock has a 50-day simple moving average of $33.88 and a 200 day simple moving average of $42.18.

ScanSource Inc. (SCSC) reported its third-quarter earnings for 2025, revealing a mixed financial performance. The company’s earnings per share (EPS) exceeded expectations at $0.86, surpassing the ...

Welcome to the ScanSource quarterly earnings conference call. (Operator Instructions) Today's call is being recorded. (Operator Instructions) I would now like to turn the call over to Mary Gentry, ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

While its fabled takeover of Seagen is yet to materialise, Merck & Co has continued to bolster its pipeline with smaller deals – with its latest a $1.35 billion agreement to buy Imago ...

ScanSource Thursday reported a drop in its third fiscal quarter 2025 revenue but said that it expects growth for this year as a whole despite macroeconomic environment fluctuations. Steve Jones ...

Bomedemstat was the main asset in MSD's $1.35 billion acquisition of Imago BioSciences, which closed last year, one of a series of bolt-on deals the company has embarked upon to build its pipeline ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...